NVDA
NVIDIA
-- 139.640 TSLA
Tesla
-- 433.695 PLTR
Palantir
-- 80.920 AMD
Advanced Micro Devices
-- 124.975 RGTI
Rigetti Computing
-- 11.1512 
$BioVie (BIVI.US)$ NEWS BioVie to Present Data Showing How N...
NEWS
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation Rhea-AI Impact (Low) Rhea-AI Sentiment (Neutral) Tags conferences Rhea-AI Summary BioVie Inc. (Nasdaq: BIVI) announced the approval of the non-proprietary name 'bezisterim' for NE3107, a potential treatment for neurological disorders. The company will present data at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit on how bezisterim impacts genes associated with dementia, metabolism, and inflammation. Share on X Share on Reddit Share on Facebook 04/18/2024 - 05:00 AM Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, Massachusetts April 23-25. Additionally, the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “bezisterim” as the non-proprietary (generic) name for NE3107, an orally active partial NF-κB inhibitor product candidate being studied in Parkinson’s Disease and Alzheimer’s Disease. The oral and poster presentations 12th Annual Alzheimer's & Parkinson's Drug Development Summit will provide additional details on how bezisterim appears to have an impact on DNA methylation on 5 different “clocks” measuring biological age and that the extent of DNA methylation is correlated to a series of clinical measures. The oral presentation titled “Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probably Alzheimer’s Disease” will be presented by Christopher L. Reading, BioVie’s Senior Vice President, Alzheimer’s Disease Program, on Wednesday, April 24 at 2:30 p.m. EDT. The poster with the same title will be presented at 6:45 p.m. on the same day. Details of the presented data and conclusions will be announced once the presentations are made public at the conference. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company conducted and reported efficacy data on its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of bezisterim in Parkinson’s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S Food and Drug Administration (“FDA”) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/. Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com What is the non-proprietary name approved for NE3107 by the USAN Council and WHO INN expert committee? Where will BioVie present data on NE3107 and bezisterim? Who will present the oral presentation on NE3107 at the conference? When will the oral presentation on NE3107 take place at the conference? What will the poster presentation focus on at the conference? Stock BIVI logo BioVie Inc NASDAQ:BIVI BIVI Rankings #5007 Ranked by Market Cap N/A Ranked by Dividends BIVI Latest News Apr 12, 2024 Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Mar 11, 2024 BioVie Announces Pipeline Update and Near-Term Clinical Priorities Mar 6, 2024 BioVie Inc. Announces Closing of Public Offering Mar 4, 2024 BioVie Inc. Announces Pricing of Public Offering Mar 1, 2024 BioVie Inc. Announces Proposed Public Offering of Common Stoc BIVI Stock Data INDUSTRY Pharmaceutical Preparation Manufacturing SECTOR Manufacturing WEBSITE Link TAGS Biotechnology, Health Technology About BIVI biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo Explore About Rhea-AI Sitemap Legal Terms of Use Cookie Notice Privacy Policy Links RSS feed Patreon Discord Server Facebook Reddit © 2020-2024 StockTitan.net
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Aman dhillon : dude that is looks like bible u write pls tell me when its going up ..i m 68% down
Vatnikas Aman dhillon : U need to wait Prese Release